Michael Schell, PhD

Statistical examination is critical to glean true biological differences from technological artifacts, providing patients the best personalized treatment.

Associations

• Biostatistics and Bioinformatics
• Melanoma & Skin Cancer Center of Excellence
• Lung Cancer Center of Excellence
• Cancer Epidemiology Program
• Cancer Chemoprevention Research Interest Group
• Experimental Therapeutics Program

Education & Training

Graduate:

• Florida State University, PhD - Statistics
• Florida State University, MS - Statistics

Dr. Schell has led the development of a statistical method to analyze AQUA (Automated Quantitative Analysis)-generated tissue microarray (TMA) data. The method is a 7-step procedure which works quite well for identifying and resolving technical problems when two highly correlated variables are available.  This method provides a practical and efficient way of identifying an appropriate transformation (square-root, quarter-root or log), if needed, of AQUA scores that can be used to satisfy the normality assumption required by most of statistical procedures.  This methodology identifies and adjusts for possible row or column spatial bias effects in a 20 x 17 rectangular plate used in the AQUA machine, which arise due to technical processing effects. The method facilitates the identification of possible outliers or leverage data points in the data due to, for instance, air bubbles. Dr. Schell is a member of the Cancer Biomarkers Study Section.  He is also the statistician for a large integral-biomarker phase III multi-center clinical trial in lung cancer.

• Al-Toubah T, Schell MJ, Morse B, Haider M, Valone T, Strosberg J. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. ESMO Open. 2024 Mar.9(4):102386. Pubmedid: 38507897. Pmcid: PMC10966166.
• Dickey BL, Putney RM, Schell MJ, Berglund AE, Amelio AL, Caudell JJ, Chung CH, Giuliano AR. Identification of a Biomarker Panel from Genome-Wide Methylation to Detect Early HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila). 2024 Apr.17(4):169-176. Pubmedid: 38286404. Pmcid: PMC10987272.
• Heine J, Fowler EEE, Berglund A, Schell MJ, Eschrich S. Techniques to produce and evaluate realistic multivariate synthetic data. Sci Rep. 2023 Jul.13(1):12266. Pubmedid: 37507387. Pmcid: PMC10382509.
• Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
• Kumar NB, Bahl S, Dhillon J, Poch M, Manley B, Li R, Schell M, Powsang J. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials. Cancers (Basel). 2023 Feb.15(4). Pubmedid: 36831597. Pmcid: PMC9954186.
• Lee B, Chehab SS, Fan W, Schell MJ, Kirtane KS, Shah AB. Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer. J Oncol Pharm Pract. 2023 Dec. Pubmedid: 38043938.
• Dukes CW, Rossetti RA, Hensel JA, Snedal S, Cubitt CL, Schell MJ, Abrahamsen M, Isaacs-Soriano K, Kennedy K, Mangual LN, Whiting J, Martinez-Brockhus V, Islam JY, Rathwell J, Beatty M, Hall AM, Abate-Daga D, Giuliano AR, Pilon-Thomas S. SARS-CoV-2 antibody response duration and neutralization following natural infection. J Clin Virol Plus. 2023 Aug.3(3). Pubmedid: 37654784. Pmcid: PMC10470471.
• Amorrortu RP, Zhao Y, Fenske NA, Cherpelis BS, Messina JL, Giuliano AR, Sondak VK, Schell MJ, Mckay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections. J Infect Dis. 2022 Sep.226(7):1162-1174. Pubmedid: 35022780. Pmcid: PMC9518839.
• Dickey BL, Nedjai B, Preece MD, Schell MJ, Boulware D, Whiting J, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Kennedy K, Chung CH, Giuliano AR. Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Med. 2022 Oct.11(20):3735-3742. Pubmedid: 35619332. Pmcid: PMC9582688.
• Schell MJ, Gwede CK, Friedman M. Physician Adenoma Detection Rates and Colorectal Cancer. Jama. 2022 Oct.328(14):1462. Pubmedid: 36219411.
• Yang M, Davis TB, Pflieger L, Nebozhyn MV, Loboda A, Wang H, Schell MJ, Thota R, Pledger WJ, Yeatman TJ. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer. 2022 Mar.22(1):256. Pubmedid: 35272617. Pmcid: PMC8908604.
• Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022 Mar.28(3):556-563. Pubmedid: 35081021. Pmcid: PMC8888241.
• Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Jun.20(3):252-259. Pubmedid: 35249821.
• Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35676062. Pmcid: PMC9185557.
• Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Jun.28(11):2329-2338. Pubmedid: 35344035. Pmcid: PMC9167762.
• Tan ES, Fan W, Knepper TC, Schell MJ, Sahin IH, Fleming JB, Xie H. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer. Target Oncol. 2022 Jul.17(4):483-492. Pubmedid: 35767139.
• Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Dec.28(24):5317-5329. Pubmedid: 36215121. Pmcid: PMC10324027.
• Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. Stat Med. 2022 Apr.41(8):1361-1375. Pubmedid: 34897773.
• Rollison DE, Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Giuliano AR, Sondak VK, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M. Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Res. 2021 Sep.81(17):4628-4638. Pubmedid: 34266893. Pmcid: PMC8416805.
• Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Sondak VK, Giuliano AR, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2021 Sep.30(9):1761-1764. Pubmedid: 34187857. Pmcid: PMC8419098.
• Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Sep.20(3):e155-e164. Pubmedid: 33775560.
• Thota R, Yang M, Pflieger L, Schell MJ, Rajan M, Davis TB, Wang H, Presson A, Pledger WJ, Yeatman TJ. APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers (Basel). 2021 Oct.13(21). Pubmedid: 34771559. Pmcid: PMC8582550.
• Rollison DE, Messina JL, Cherpelis BS, Fenske NA, Schell MJ, Adeegbe DO, Zhao Y, Amorrortu RP, Akuffo AA, Hesterberg RS, Epling-Burnette PK. Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. Front Med (Lausanne). 2021 Nov.8:735585. Pubmedid: 34796183. Pmcid: PMC8593034.
• Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
• Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer J, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol. 2021 Mar.16(3):428-438. Pubmedid: 33301984. Pmcid: PMC8549863.
• Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
• Kamal Y, Dwan D, Hoehn HJ, Sanz-Pamplona R, Alonso MH, Moreno V, Cheng C, Schell MJ, Kim Y, Felder SI, Rennert HS, Melas M, Lazaris C, Bonner JD, Siegel EM, Shibata D, Rennert G, Gruber SB, Frost HR, Amos CI, Schmit SL. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. Oncoimmunology. 2021 Mar.10(1):1862529. Pubmedid: 33763292. Pmcid: PMC7951964.
• Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, Giuliano AR, Schell MJ, Waterboer T, Pawlita M, McKay-Chopin S, Gheit T, Tommasino M, Rollison DE. Cutaneous viral infections associated with ultraviolet radiation exposure. Int J Cancer. 2021 Jan.148(2):448-458. Pubmedid: 32818302. Pmcid: PMC7754468.
• Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
• Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel). 2021 Dec.13(24). Pubmedid: 34944787. Pmcid: PMC8699355.
• Yuan Z, Frazer M, Ahmed KA, Naqvi SMH, Schell MJ, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Torres-Roca JF, Hoffe SE, Frakes JM. Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncol. 2020 Oct.16(30):2411-2420. Pubmedid: 32686956.
• Fowler EE, Berglund A, Schell MJ, Sellers TA, Eschrich S, Heine J. Empirically-derived synthetic populations to mitigate small sample sizes. J Biomed Inform. 2020 May.105:103408. Pubmedid: 32173502. Pmcid: PMC7839232.
• Yeatman TJ, Schell MJ, Sause W. Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile. JAMA Netw Open. 2020 Mar.3(3):e1919991. Pubmedid: 32150267.
• Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun.6(6):888-894. Pubmedid: 32352498. Pmcid: PMC7193528.
• DePeralta DK, Ogami T, Zhou JM, Schell MJ, Powers BD, Hodul PJ, Malafa MP, Fleming JB. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB (Oxford). 2020 Feb.22(2):241-248. Pubmedid: 31563326. Pmcid: PMC7771530.
• Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B, Martin-Gomez L, Abrahamsen M, Isaacs-Soriano KA, Wenig B, Chung CH, Caudell J. Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. Int J Cancer. 2020 Feb.146(4):1018-1030. Pubmedid: 31304592. Pmcid: PMC7787351.
• Kim DW, Schell MJ, Kim RD. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply. JAMA Oncol. 2020 Dec.6(12):1981-1982. Pubmedid: 33090188.
• Pointer DT, Roife D, Powers BD, Murimwa G, Elessawy S, Thompson ZJ, Schell MJ, Hodul PJ, Pimiento JM, Fleming JB, Malafa MP. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer. 2020 Aug.20(1):750. Pubmedid: 32782024. Pmcid: PMC7422564.
• Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
• Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2019 Oct.25(19):5961-5971. Pubmedid: 31399473. Pmcid: PMC6774882.
• Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clin Cancer Res. 2019 May.25(9):2783-2794. Pubmedid: 30765391. Pmcid: PMC6497575.
• Martin-Gomez L, Fulp WJ, Schell MJ, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Lorincz A, Wenig B, Chung CH, Caudell JJ, Giuliano AR. Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases. Oral Oncol. 2019 May.92:85-91. Pubmedid: 31010629. Pmcid: PMC6736648.
• Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res. 2019 Jul.8(Suppl 4):S404-S420. Pubmedid: 31456910. Pmcid: PMC6711387.
• Yang M, Schell MJ, Loboda A, Nebozhyn M, Li J, Teer JK, Pledger WJ, Yeatman TJ. Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations. Cancer Epidemiol Biomarkers Prev. 2019 Jul.28(7):1141-1152. Pubmedid: 31015202. Pmcid: PMC7845290.
• Al-Toubah T, Schell M, Cives M, Zhou JM, Soares H, Strosberg JR. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology. 2019 Jul.110(5):377-383. Pubmedid: 31357193. Pmcid: PMC7771542.
• Kim J, Schell MJ. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials. Oncotarget. 2019 Jul.10(42):4255-4261. Pubmedid: 31303960. Pmcid: PMC6611508.
• Rollison DE, Schell MJ, Fenske NA, Cherpelis B, Messina JL, Giuliano AR, Epling-Burnette PK, Hampras S, Amorrortu RP, Balliu J, Vijayan L, Naqvi SMH, Zhao Y, Parab K, McKay-Chopin S, Gheit T, Tommasino M. Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer Screening. J Infect Dis. 2019 Feb.219(5):711-722. Pubmedid: 30260406. Pmcid: PMC6376905.
• Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Brit J Cancer. 2019 Apr.120(8):791-796. Pubmedid: 30880334. Pmcid: PMC6474279.
• Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, Gray JE. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018 Nov.9(86):35666-35675. Pubmedid: 30479696. Pmcid: PMC6235019.
• Davis TB, Yang M, Schell MJ, Wang H, Ma L, Pledger WJ, Yeatman TJ. PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. Sci Rep. 2018 Jun.8(1):9296. Pubmedid: 29915291. Pmcid: PMC6006154.
• Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2018 Feb.117(2):150-159. Pubmedid: 28833197. Pmcid: PMC7771345.
• Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec.9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
• Li J, Smalley I, Schell MJ, Smalley KSM, Chen YA. SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. Bioinformatics. 2017 Sep.33(18):2951-2953. Pubmedid: 28472395. Pmcid: PMC5870537.
• Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Oct.84:304-314. Pubmedid: 28863385. Pmcid: PMC5822441.
• Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Nov.8(58):99093-99103. Pubmedid: 29228755. Pmcid: PMC5716795.
• Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May.8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
• Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Biometrics. 2017 Jun.73(2):687-695. Pubmedid: 27669414. Pmcid: PMC6093291.
• Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017 Feb.18(2):202-211. Pubmedid: 27993569. Pmcid: PMC7771305.
• Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplant. 2017 Apr.52(4):627-629. Pubmedid: 27991896. Pmcid: PMC5382111.
• Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct.7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
• Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist. 2016 Oct.21(10):1163-1164. Pubmedid: 27694157. Pmcid: PMC5061534.
• Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ. Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Med Genomics. 2016 Oct.9(1):65. Pubmedid: 27756306. Pmcid: PMC5069826.
• Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun. 2016 Jun.7:11743. Pubmedid: 27302369. Pmcid: PMC4912618.
• Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn M, Loboda A, Bloom G, Yeatman TJ. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clin Cancer Res. 2016 Feb.22(3):734-745. Pubmedid: 26446941. Pmcid: PMC4802496.
• Weber J, Gibney G, Kudchadkar RR, Yu B, Cheng P, Martinez AJ, Kroeger J, Richards A, McCormick L, Moberg V, Cronin H, Zhao X, Schell M, Chen YA. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res. 2016 Apr.4(4):345-353. Pubmedid: 26873574. Pmcid: PMC4818672.
• Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015 Sep.121(18):3252-3260. Pubmedid: 26038193. Pmcid: PMC4904725.
• Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
• Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One. 2015 May.10(5):e0126670. Pubmedid: 25974029. Pmcid: PMC4431733.
• Chellappan SP, Pillai S, Trevino JG, Rawal B, Singh S, Kovacs M, Li X, Schell MJ, Haura EB, Bepler G. β-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition. Cancer Res. 2015 Mar.75(6):1009-1020. Pubmedid: 25600647. Pmcid: PMC4359962.
• Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh LF, Eysmans C, Richards A, Schell MJ, Fisher K, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos IH, Weber J. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015 Feb.21(4):712-720. Pubmedid: 25524312. Pmcid: PMC4620684.
• Cives M, Kunz P, Morse B, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb.22(1):1-9. Pubmedid: 25376618. Pmcid: PMC4643672.
• Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015 Apr.54(4):487-492. Pubmedid: 25549537. Pmcid: PMC4743650.
• Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control. 2015 Apr.22(2):235-241. Pubmedid: 26068771.
• Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr.51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
• Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep.4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
• Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Sep.67(9):764-767. Pubmedid: 25004944. Pmcid: PMC4743643.
• Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients. Biol Res Nurs. 2014 Oct.16(4):429-437. Pubmedid: 24477514. Pmcid: PMC4604564.
• Lengacher CA, Reich RR, Kip KE, Barta M, Ramesar S, Paterson CL, Moscoso MS, Carranza I, Budhrani PH, Kim SJ, Park HY, Jacobsen PB, Schell MJ, Jim HS, Post-White J, Farias JR, Park JY. Influence of mindfulness-based stress reduction (MBSR) on telomerase activity in women with breast cancer (BC). Biol Res Nurs. 2014 Oct.16(4):438-447. Pubmedid: 24486564. Pmcid: PMC4559344.
• Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar.20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
• Han G, Schell MJ, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med. 2014 Jan.33(1):59-73. Pubmedid: 23900779. Pmcid: PMC3913785.
• Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014 Aug.50(8):765-769. Pubmedid: 24954065. Pmcid: PMC4593395.
• Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013 Oct.20(4):248-254. Pubmedid: 24077401. Pmcid: PMC4516026.
• Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct.36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
• Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2013 Nov.9:705. Pubmedid: 24189400. Pmcid: PMC4039310.
• Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar.119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
• Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar.2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
• Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
• Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul.31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
• Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep.23(9):2335-2341. Pubmedid: 22317769. Pmcid: PMC4559904.
• Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012 Oct.4(4):348-356. Pubmedid: 23814641. Pmcid: PMC3693095.
• Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May.48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
• Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May.118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
• Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar.33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
• Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan.2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
• Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathxxx. 2012 Aug.34(6):592-596. Pubmedid: 22814318. Pmcid: PMC4634647.
• Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct.129(8):1963-1969. Pubmedid: 21154746. Pmcid: PMC3776586.
• Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun.64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
• Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Jul.31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
• Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011 Jan.178(1):69-78. Pubmedid: 21224045. Pmcid: PMC3069904.
• Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG. Suicide in patients with pancreatic cancer. Cancer. 2011 Feb.117(3):642-647. Pubmedid: 20824626. Pmcid: PMC4704452.
• Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2011 Apr.90(4):423-428. Pubmedid: 21153898. Pmcid: PMC3053415.
• Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar.28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
• Chen JJ, Roberson PK, Schell MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control. 2010 Jan.17(1):58-62. Pubmedid: 20010520.
• Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2010 Feb.28(2):172-180. Pubmedid: 19968494. Pmcid: PMC3565222.
• Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol. 2010 Apr.5(4):484-490. Pubmedid: 20107425. Pmcid: PMC2861290.
• Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr.45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
• Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep.8(17):1671-1679. Pubmedid: 19633423. Pmcid: PMC3839311.
• Lee JH, Schell MJ, Roetzheim R. Analysis of group randomized trials with multiple binary endpoints and small number of groups. PLoS One. 2009 Oct.4(10):e7265. Pubmedid: 19844579. Pmcid: PMC2760209.
• Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul.175(1):324-333. Pubmedid: 19497997. Pmcid: PMC2708818.
• Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb.16(2):195-201. Pubmedid: 19097905.
• Lee J-H, Miladinovic B, Schell MJ. Statistical tutorial notes: analysis of two group comparisons, a practical guide. Med Probl Perform Art. 2009 Dec.166-169.
• Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec.27(34):5808-5815. Pubmedid: 19884554. Pmcid: PMC2793001.
• Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May.112(9):2021-2029. Pubmedid: 18300255.
• Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar.26(7):1142-1147. Pubmedid: 18309950.
• Zheng Z, Li X, Schell M, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008 Jun.112(12):2765-2773. Pubmedid: 18442042. Pmcid: PMC3857609.
• Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul.45(3):150-159. Pubmedid: 18582621.
• Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. J Biopharm Stat. 2008.18(5):841-852. Pubmedid: 18781520. Pmcid: PMC2717790.
• Pavic D, Schell M, Dancel R, Sultana S, Lin L, Sejpal S, Pisano E. Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients. Acad Radiol. 2007 May.14(5):553-560. Pubmedid: 17434069.
• Lloyd-Burton SM, Yu JC, Irvine RF, Schell MJ. Regulation of inositol 1,4,5-trisphosphate 3-kinases by calcium and localization in cells. J Biol Chem. 2007 Mar.282(13):9526-9535. Pubmedid: 17284449.
• Schell M, Yankaskas B, Ballard-Barbash R, Qaqish B, Barlow W, RosenbergRD, Smith-Bindman R. Evidence-based target recall rates for screening mammography. Radiology. 2007 Jun.243(3):681-689. Pubmedid: 17517927.
• Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006 May.12(9):2662-2669. Pubmedid: 16675557.
• Stinchcombe T, Choi J, Schell M, Mears A, Jones P, Nachtsheim R, Socinski M. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer. 2006 Feb.51(2):237-243. Pubmedid: 16378657.
• Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec.108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
• Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 2005 Jun.115(3):368-376. Pubmedid: 15688379.
• Ivanova A, Qaqish B, Schell M. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun.61(2):540-545. Pubmedid: 16011702.
• Titus MA, Gregory CW, Ford OH , Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005 Jun.11(12):4365-4371. Pubmedid: 15958619.
• Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005 Jun.28(3):270-276. Pubmedid: 15923800.
• Titus M, Schell M, Lih F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005 Jul.11(13):4653-4657. Pubmedid: 16000557.
• Hensing T, Schell M, Lee J, Socinski M. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb.47(2):253-259. Pubmedid: 15639724.
• Mohler J, Gaston K, Moore D, Schell M, Cohen B, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004 Jun.171(6 Pt 1):2277-2280. Pubmedid: 15126802.
• Yankaskas B, Schell M, Miglioretti D. Recall and detection rates in screening mammography. Cancer. 2004.101(11):2710-2712. Pubmedid: 15499596.
• Abrahamson P, Dunlap L, Amamoo M, Schell M, Braeuning M, Pisano E. Factors predicting successful needle-localized breast biopsy. Acad Radiol. 2003 Jun.10(6):601-606. Pubmedid: 12809412.
• Hensing T, Peterman A, Schell M, Lee J, Socinski M. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug.98(4):779-788. Pubmedid: 12910523.
• Socinski MA, Neubauer MA, Olivares J, Ketchel S, Tynan M, Moore M, Lee JH, Davis K, Schell M, Garfield D. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer. 2003 Apr.40(1):91-97. Pubmedid: 12660013.
• Socinski M, Schell M, Bakri K, Peterman A, Lee J, et al.. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 2002 Sep.95(6):1265-1273. Pubmedid: 12216094.
• McHale M, Berman M, Keefe K, Schell M, Peng Y, Monk B. Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3. J Low Genit Tract Dis. 2002 Oct.6(4):220-224. Pubmedid: 17051026.
• Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002 Nov.76(5):1126-1137. Pubmedid: 12399289.
• Socikski M, Schell M, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee J, et al.. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002 Mar.20(5):1335-1343. Pubmedid: 11870177.
• Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002 Feb.277(8):6504-6510. Pubmedid: 11724773.
• Yankaskas BC, Schell MJ, Bird RE, Desrochers DA. Reassessment of breast cancers missed during routine screening mammography: a community-based study. Ajr Am J Roentgenol. 2001 Sep.177(3):535-541. Pubmedid: 11517043.
• Yankaskas BC, Cleveland RJ, Schell MJ, Kozar R. Association of recall rates with sensitivity and positive predictive values of screening mammography. Ajr Am J Roentgenol. 2001 Sep.177(3):543-549. Pubmedid: 11517044.
• Godley PA, Rathore SS, Kshirsagar AV, Amamoo MA, Schell MJ, Freeman J, Harris RP. Retrospective classification of prostate-specific antigen tests: differentiating screening from diagnostic clinical encounters. J Clin Epidemiol. 2001 Sep.54(9):884-888. Pubmedid: 11520647.
• Pisano ED, Britt GG, Lin Y, Schell MJ, Burns CB, Brown ME. Factors affecting phantom scores at annual mammography facility inspections by the U.S. Food and Drug Administration. Acad Radiol. 2001 Sep.8(9):864-870. Pubmedid: 11724041.
• Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001 Sep.92(5):1213-1223. Pubmedid: 11571735.
• Charles MJ, Schell MJ, Willman E, Gross HB, Lin Y, Sonnenberg S, Graham ML. Organochlorines and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in cancerous and noncancerous breast tissue: do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer?. Arch Environ Contam Toxicol. 2001 Oct.41(3):386-395. Pubmedid: 11503078.
• Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2001 Oct.10(10):1029-1035. Pubmedid: 11588128.
• O'Malley MS, Earp JA, Hawley ST, Schell MJ, Mathews HF, Mitchell J. The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening?. Am J Public Health. 2001 Jan.91(1):49-54. Pubmedid: 11189825. Pmcid: PMC1446507.
• Poole ME, Sailer SL, Rosenman JG, Tepper JE, Weissler MC, Shockley WW, Yarbrough WG, Pillsbury HC, Schell MJ, Bernard SA. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch Otolaryngol Head Neck Surg. 2001 Dec.127(12):1446-1450. Pubmedid: 11735812.
• Duell EJ, Millikan RC, Savitz DA, Schell MJ, Newman B, Tse CJ, Sandler DP. Reproducibility of reported farming activities and pesticide use among breast cancer cases and controls. A comparison of two modes of data collection. Ann Epidemiol. 2001 Apr.11(3):178-185. Pubmedid: 11248581.
• Serody JS, Berrey MM, Albritton K, O'Brien SM, Capel EP, Bigelow SH, Weber DJ, Gabriel, Wiley JM, Schell MJ, Gilligan PH, Shea TC. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2000 Sep.26(5):533-538. Pubmedid: 11019843.
• Duell EJ, Millikan RC, Savitz DA, Newman B, Smith JC, Schell MJ, Sandler DP. A population-based case-control study of farming and breast cancer in North Carolina. Epidemiology. 2000 Sep.11(5):523-531. Pubmedid: 10955404.
• Gillenwater HH, Tynan M, Natoli S, Schell MJ, Socinski MA. Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial. Clin Lung Cancer. 2000 Nov.2(2):133-138. Pubmedid: 14731324.
• Braeuning MP, Earp JL, O'Brien SM, Schell MJ, Denham AC, Pisano ED, O'Malley MS. Informing patients of diagnostic mammography results: mammographer's opinions. Acad Radiol. 2000 May.7(5):335-340. Pubmedid: 10803613.
• Brylawski BP, Cohen SM, Cordeiro-Stone M, Schell MJ, Kaufman DG. On the relationship of matrix association and DNA replication. Crit Rev Eukaryot Gene Expr. 2000 Jul.10(1):91-99. Pubmedid: 10813397.
• Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, Liu ET, Conway K. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000 Jan.18(2):267-274. Pubmedid: 10637239.
• Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000 Jan.9(1):65-71. Pubmedid: 10667465.
• Serody JS, Sparks SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL, Gabriel DA, Wiley JM, Brecher ME, Schell MJ, Folds J, Shea TC. Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Tr. 2000 Dec.6(4A):434-440. Pubmedid: 10975512.
• Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer. 2000 Aug.89(3):534-542. Pubmedid: 10931452.
• Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000 Apr.151(7):703-714. Pubmedid: 10752798.
• Pisano ED, Schell M, Rollins J, Burns CB, Hall B, Lin Y, Braeuning MP, Burke E, Holliday J. Has the mammography quality standards act affected the mammography quality in North Carolina?. Ajr Am J Roentgenol. 2000 Apr.174(4):1089-1091. Pubmedid: 10749257.
• Osann KE, Lowery JT, Schell MJ. Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. Lung Cancer. 2000 Apr.28(1):1-10. Pubmedid: 10704703.
• Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med. 1999 Jun.8(5):623-630. Pubmedid: 10839648.
• Koizumi S, Bootman MD, Bobanović LK, Schell MJ, Berridge MJ, Lipp P. Characterization of elementary Ca2+ release signals in NGF-differentiated PC12 cells and hippocampal neurons. Neuron. 1999 Jan.22(1):125-137. Pubmedid: 10027295.
• Godley PA, Schell MJ. Adjusted odds ratios under nondifferential misclassification: application to prostate cancer. J Clin Epidemiol. 1999 Feb.52(2):129-136. Pubmedid: 10201653.
• Braeuning MP, Cooper HW, O'Brien S, Burns CB, Washburn DB, Schell MJ, Pisano ED. Effects of processing conditions on mammographic image quality. Acad Radiol. 1999 Aug.6(8):464-470. Pubmedid: 10480042.
• Wester RC, Hui X, Hartway T, Maibach HI, Bell K, Schell MJ, Northington DJ, Strong P, Culver BD. In vivo percutaneous absorption of boric acid, borax, and disodium octaborate tetrahydrate in humans compared to in vitro absorption in human skin from infinite and finite doses. Toxicol Sci. 1998 Sep.45(1):42-51. Pubmedid: 9848109.
• Cooper DM, Schell MJ, Thorn P, Irvine RF. Regulation of adenylyl cyclase by membrane potential. J Biol Chem. 1998 Oct.273(42):27703-27707. Pubmedid: 9765307.
• Yeomans Kinney A, Vernon SW, Shui W, Weber DV, Schell M, Vogel VG. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer. Cancer Epidemiol Biomarkers Prev. 1998 Jul.7(7):591-595. Pubmedid: 9681527.
• Pisano ED, Earp J, Schell M, Vokaty K, Denham A. Screening behavior of women after a false-positive mammogram. Radiology. 1998 Jul.208(1):245-249. Pubmedid: 9646820.
• George S, Schell MJ, Detterbeck FC, Socinski MA. Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know. Oncologist. 1998 Feb.3(1):35-44. Pubmedid: 10388082.
• Wester RC, Hartway T, Maibach HI, Schell MJ, Northington DJ, Culver BD, Strong PL. In vitro percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in human skin: a summary. Biol Trace Elem Res. 1998.66(1-3):111-120. Pubmedid: 10050913.
• Wester RC, Hui X, Maibach HI, Bell K, Schell MJ, Northington DJ, Strong P, Culver BD. In vivo percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in humans: a summary. Biol Trace Elem Res. 1998.66(1-3):101-109. Pubmedid: 10050912.
• Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ, Meyskens FL. Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. Am J Ther. 1997 Apr.4(4):134-140. Pubmedid: 10423603.
• Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci U S A. 1997 Apr.94(7):3396-3401. Pubmedid: 9096405. Pmcid: PMC20381.
• Manetta A, Schubbert T, Chapman J, Schell MJ, Peng YM, Liao SY, Meyskens FJ. beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev. 1996 Nov.5(11):929-932. Pubmedid: 8922303.
• Stute N, Furman WL, Schell M, Evans WE. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci. 1995 Jul.84(7):824-828. Pubmedid: 7562431.
• Dantas ZN, Araujo E, Tadir Y, Berns MW, Schell MJ, Stone SC. Effect of freezing on the relative escape force of sperm as measured by a laser optical trap. Fertil Steril. 1995 Jan.63(1):185-188. Pubmedid: 7805910.
• Wong DH, Weber EC, Schell MJ, Wong AB, Anderson CT, Barker SJ. Factors associated with postoperative pulmonary complications in patients with severe chronic obstructive pulmonary disease. Anesth Analg. 1995 Feb.80(2):276-284. Pubmedid: 7818113.
• Wilder-Smith P, Arrastia AM, Schell MJ, Liaw LH, Grill G, Berns MW. Effect of ND:YAG laser irradiation and root planing on the root surface: structural and thermal effects. J Periodontol. 1995 Dec.66(12):1032-1039. Pubmedid: 8683415.
• Schell MJ, Molliver ME, Snyder SH. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A. 1995 Apr.92(9):3948-3952. Pubmedid: 7732010. Pmcid: PMC42079.
• Wyss P, Tromberg BJ, Wyss MT, Krasieva T, Schell M, Berns MW, Tadir Y. Photodynamic destruction of endometrial tissue with topical 5-aminolevulinic acid in rats and rabbits. Am J Obstet Gynecol. 1994 Nov.171(5):1176-1183. Pubmedid: 7977515.
• Monk BJ, Chapman JA, Johnson GA, Brightman BK, Wilczynski SP, Schell MJ, Fan H. Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol. 1994 Nov.171(5):1193-1198. Pubmedid: 7977518.
• Kimel S, Svaasand LO, Hammer-Wilson M, Schell MJ, Milner TE, Nelson JS, Berns MW. Differential vascular response to laser photothermolysis. J Invest Dermatol. 1994 Nov.103(5):693-700. Pubmedid: 7963659.
• Van Nostrand KM, Lucci JA, Schell M, Berman ML, Manetta A, DiSaia PJ. Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol. 1994 Nov.55(2):234-237. Pubmedid: 7959290.
• Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci U S A. 1994 May.91(10):4214-4218. Pubmedid: 7514300. Pmcid: PMC43755.
• Peabody TD, Monson D, Montag A, Schell MJ, Finn H, Simon MA. A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities. J Bone Joint Surg Am. 1994 Aug.76(8):1167-1173. Pubmedid: 8056797.
• Hurwitz CA, Schell MJ, Pui CH, Crist WM, Behm F, Mirro J. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Pediatr Oncol. 1993 Feb.21(1):1-7. Pubmedid: 8426571.
• Wile AG, Hourani L, Schell MJ. The contributions of patient factors, physician delay, and tumor biology to the outcome of gastric cancer. Am Surg. 1993 Dec.59(12):850-854. Pubmedid: 8256942.
• Santana VM, Schell MJ, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov.10(5):457-462. Pubmedid: 1464010.
• Pui CH, Carroll AJ, Raimondi SC, Schell MJ, Head DR, Shuster JJ, Crist WM, Borowitz MJ, Link MP, Behm FG. Isochromosomes in childhood acute lymphoblastic leukemia: a collaborative study of 83 cases. Blood. 1992 May.79(9):2384-2391. Pubmedid: 1571550.
• Angel CA, Pratt CB, Rao BN, Schell MJ, Parham DM, Lobe TE, Fleming ID. Carcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescents. Cancer. 1992 Mar.69(6):1487-1491. Pubmedid: 1311626.
• Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar.10(3):364-370. Pubmedid: 1346800.
• Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992 Jun.79(11):2849-2854. Pubmedid: 1375115.
• Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeirio R, Roberts WM, Mahmoud H, Belt J, Crom W. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992 Jun.6 Suppl 2:39-43. Pubmedid: 1374492.
• Schell MJ, Ochs JJ, Schriock EA, Carter M. A method of predicting adult height and obesity in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 Jan.10(1):128-133. Pubmedid: 1727914.
• Behm FG, Raimondi SC, Schell MJ, Look AT, Rivera GK, Pui CH. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood. 1992 Feb.79(4):1011-1016. Pubmedid: 1531305.
• Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol. 1992 Feb.66(2):1129-1138. Pubmedid: 1731092. Pmcid: PMC240817.
• Eguiguren JM, Schell MJ, Crist WM, Kunkel K, Rivera GK. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood. 1992 Feb.79(4):871-875. Pubmedid: 1737097.
• Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991 Sep.50(3):308-313. Pubmedid: 1680593.
• Pui CH, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro J, Crist WM, Behm FG. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 1991 Sep.78(5):1327-1337. Pubmedid: 1878594.
• Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, Schell MJ, Wilimas JA. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991 Mar.118(3):377-382. Pubmedid: 1999776.
• Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol. 1991 Mar.9(3):416-422. Pubmedid: 1671875.
• Pui CH, Schell MJ, Vodian MA, Kline S, Mirro J, Crist WM, Behm FG. Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia. Leukemia. 1991 Mar.5(3):249-254. Pubmedid: 1901614.
• Mahmoud H, Schell M, Pui CH. Cholelithiasis after treatment for childhood cancer. Cancer. 1991 Mar.67(5):1439-1442. Pubmedid: 1899356.
• Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol. 1991 Mar.9(3):400-405. Pubmedid: 1999710.
• Koehler M, Schell MJ, Behm FG, Raimondi SC, Woodruff LS, Mirro J. Expression of a novel surface antigen MKW in childhood acute leukemia has prognostic significance. Leukemia. 1991 Jan.5(1):41-48. Pubmedid: 1999957.
• Rao BN, Santana VM, Parham D, Pratt CB, Fleming ID, Hudson M, Fontanesi J, Philippe P, Schell MJ. Pediatric nonrhabdomyosarcomas of the extremities. Influence of size, invasiveness, and grade on outcome. Arch Surg. 1991 Dec.126(12):1490-1495. Pubmedid: 1842178.
• Evans WE, Schell MJ, Pui CH. MTX clearance is more important for intermediate-risk ALL. J Clin Oncol. 1990 Jun.8(6):1115-1116. Pubmedid: 2348226.
• Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, Crist WM, Mirro J. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood. 1990 Jan.75(1):198-202. Pubmedid: 2294988.
• Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol. 1990 Jan.8(1):67-74. Pubmedid: 2295912.
• Kalwinsky DK, Raimondi SC, Schell MJ, Mirro J, Santana VM, Behm F, Dahl GV, Williams D. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol. 1990 Jan.8(1):75-83. Pubmedid: 2295913.
• Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 1990 Jan.75(1):174-179. Pubmedid: 2136802.
• Pinto A, Grant LH, Hayes FA, Schell MJ, Parham DM. Immunohistochemical expression of neuron-specific enolase and Leu 7 in Ewing's sarcoma of bone. Cancer. 1989 Sep.64(6):1266-1273. Pubmedid: 2670185.
• Hutchinson RE, Kunkel KD, Schell MJ, Jackson CW, Nelson EJ, Wang WC, Fischl SJ, Taylor LB, Garcez RB, Pui CH. Beneficial effect of brief pre-transfusion incubation of platelets at 37 degrees C. Lancet. 1989 May.1(8645):986-988. Pubmedid: 2565517.
• Lauer ME, Mulhern RK, Schell MJ, Camitta BM. Long-term follow-up of parental adjustment following a child's death at home or hospital. Cancer. 1989 Mar.63(5):988-994. Pubmedid: 2914304.
• Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989 Jun.7(6):754-760. Pubmedid: 2715805.
• Carter M, Kalwinsky DK, Dahl GV, Santana VM, Mason CA, Schell MJ. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia. 1989 Apr.3(4):298-302. Pubmedid: 2927178.
• Schell MJ, Morrison M. A statistical model of the timing mechanism of the erythrocyte life-span. Blood Cells. 1988 Nov.14(1):297-311. Pubmedid: 3179458.
• Pui CH, Kalwinsky DK, Schell MJ, Mason CA, Mirro J, Dahl GV. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol. 1988 Jun.6(6):1008-1013. Pubmedid: 3373258.
• Ribeiro RC, Pui CH, Schell MJ. Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer. 1988 Feb.61(3):589-592. Pubmedid: 3276382.
• Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987 Jun.316(26):1627-1632. Pubmedid: 3495732.
• Parkinson JF, Akard LP, Schell MJ, Gabig TG. Cell-free activation of phagocyte NADPH-oxidase: tissue and differentiation-specific expression of cytosolic cofactor activity. Biochem Bioph Res Co. 1987 Jun.145(3):1198-1204. Pubmedid: 3038092.
• Meyer WH, Schell MJ, Kumar AP, Rao BN, Green AA, Champion J, Pratt CB. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer. 1987 Jan.59(2):374-379. Pubmedid: 3542182.
• Gabig TG, English D, Akard LP, Schell MJ. Regulation of neutrophil NADPH oxidase activation in a cell-free system by guanine nucleotides and fluoride. Evidence for participation of a pertussis and cholera toxin-insensitive G protein. J Biol Chem. 1987 Feb.262(4):1685-1690. Pubmedid: 3027097.

• Title: Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION)
  Sponsor: Nat Institutes of Health
  PI: Giuliano, A., Core PI/Director: Schell, M.